HTTIFHIGHTIDE THERAPEUTICS INC

About HIGHTIDE THERAPEUTICS INC (HTTIF)

HIGHTIDE THERAPEUTICS INC (HTTIF) is a N/A company headquartered in Shenzhen, China whose shares trade over-the-counter on the Pink tier.

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease.

HTTIF key facts

Ticker symbol

HTTIF

Market tier

Pink

Headquarters

Shenzhen, China

Shares outstanding

259,688,923

Reporting standard

International Reporting: Hong Kong Stock Exchange

Audit status

Not Available

Fiscal year end

12/31

Explore more: Pink stocks · OTC stocks starting with H